Has the Enemy "MET" Its Match? Subgroup Analysis Results from VISION Study.

Authors :: Rosner S
Spira AI
Source :: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Mar 15; Vol. 28 (6), pp. 1055-1057.
Publication Year :: 2022
Abstract: Emerging therapies have recently received approval for the treatment of MET exon 14 skipping non-small cell lung cancer (NSCLC). Further characterization of these therapies, such as tepotinib, is needed to identify patient subgroups most likely to derive benefit from these novel agents. See related article by Le et al., p. 1117.<br /> (©2022 American Association for Cancer Research.)

Subjects :: Exons
Humans
Mutation
Proto-Oncogene Proteins c-met genetics
Carcinoma, Non-Small-Cell Lung drug therapy
Carcinoma, Non-Small-Cell Lung genetics
Lung Neoplasms drug therapy
Lung Neoplasms genetics

Language :: English
ISSN :: 1557-3265
Volume :: 28
Issue :: 6
Database :: MEDLINE
Journal :: Clinical cancer research : an official journal of the American Association for Cancer Research
Publication Type :: Editorial & Opinion
Accession number :: 34983790
Full Text :: https://doi.org/10.1158/1078-0432.CCR-21-4109